Who are DM-1992's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lybalvi, Korsuva, SAMIDORPHAN L-MALATE, Olinvyk, BENZHYDROCODONE, Symproic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dm-1992.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DM-1992 — Competitive Intelligence Brief

DM-1992 (DM-1992) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: opioid. Area: Pain.

phase 2 opioid opioid receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

DM-1992 (DM-1992) — Depomed. DM-1992 is a small molecule that targets the central nervous system to treat pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DM-1992 TARGET	DM-1992	Depomed	phase 2	opioid	opioid receptor
Lybalvi	SAMIDORPHAN	Alkermes Inc	marketed	Atypical Antipsychotic [EPC]	Mu-type opioid receptor	2021-01-01
Korsuva	DIFELIKEFALIN	Vifor Intl	marketed	Kappa Opioid Receptor Agonist	Kappa-type opioid receptor	2021-01-01
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01
Olinvyk	OLICERIDINE	Trevena	marketed		Mu-type opioid receptor	2020-01-01
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
Symproic	NALDEMEDINE	Bdsi	marketed	Opioid Antagonist	Mu-type opioid receptor	2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-08-23 — Lybalvi · 11351166 · US
2031-08-23 — Lybalvi · 11241425 · US
2031-08-23 — Lybalvi · 9126977 · US
2031-08-23 — Lybalvi · 10300054 · US
2031-08-23 — Lybalvi · 10716785 · US
2031-08-23 — Lybalvi · 11185541 · US
2031-08-23 — Lybalvi · 9517235 · US
2031-08-30 — Lybalvi · 9119848 · US
2032-02-13 — Lybalvi · 8778960 · US

Sponsor landscape (opioid class)

Norwegian University of Science and Technology · 2 drugs in this class
Cari Health Inc. · 1 drug in this class
Cedars-Sinai Medical Center · 1 drug in this class
Depomed · 1 drug in this class
Mundipharma Pharmaceuticals B.V. · 1 drug in this class
St. Olavs Hospital · 1 drug in this class
Talphera, Inc · 1 drug in this class
The Hospital for Sick Children · 1 drug in this class
University of Monastir · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DM-1992 — Competitive Intelligence Brief. https://druglandscape.com/ci/dm-1992. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab